The Two Opioid Crises Problems, Causes, and Potential Solutions: An Analytic Review
Main Article Content
Stephen E Nadeau, MD
http://orcid.org/0000-0001-5387-0462
Richard A Lawhern, PhD
http://orcid.org/0000-0001-5387-0462
Richard A Lawhern, PhD
Abstract
Introduction: The United States currently faces two opioid crises, an evolved crisis currently manifesting as widespread abuse of illicit opioids, and a crisis in pain management largely manufactured by the Centers for Disease Control and Prevention 2016 Guideline. Our goal in this paper is to identify root causes, trace the trajectory of forces unleashed over time, and define potential solutions to these crises.
Methods: Analytic review of the scientific, socioeconomic, and historical literature.
Results: The evolved crisis reflects a socioeconomic rift in American society that began in the 1970s and has resulted in disintegration of lives and rising levels of desperation, particularly among the under-educated, rendering them susceptible to the lure of illicit opioids. Present manifestations of that crisis reflect a complex series of events starting with a consensus in the late1990s that opioids were fully acceptable in the management of chronic noncancer pain. This was followed by vast opportunism by pill mills, drug distributors, and the manufacturers that supplied them; aggressive actions by state governments to rein in the pill mills; and ultimately, the development of an enormous black market in heroin and fentanyl. The manufactured crisis reflects intrusion into the medical care of patients in chronic pain by the Centers for Disease Control that had been politicized decades earlier and that, in 2016, issued a Guideline that reflected serious mis-construal of the causes of the opioid crisis. We trace this history and review the literature on treatment of addiction, including medically assisted therapy, treatment of depression, psychosocial interventions, 12-step programs, programs that seek to address the causes of desperation, supervised injection facilities, decriminalization, legalization, and the impact of the comprehensive approach taken by Portugal. We also analyze the problems affecting the Centers for Disease Control that led to the publication of its ill-advised 2016 Guideline.
Discussion: We conclude that many approaches currently being taken to treat addiction are well supported by scientific evidence but that the overall efficacy of treatment programs is not optimal and only a small fraction of all patients actually enter such programs. We also conclude that the Centers for Disease Control should have no future role in the regulation of patient care.
Keywords:
opioids, opioid crisis, CDC Guideline, CDC, pain management, illicit opioids, opioid abuse
Article Details
How to Cite
NADEAU, Stephen E; LAWHERN, Richard A.
The Two Opioid Crises Problems, Causes, and Potential Solutions: An Analytic Review.
Medical Research Archives, [S.l.], v. 11, n. 12, dec. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4846>. Date accessed: 22 dec. 2024.
doi: https://doi.org/10.18103/mra.v11i12.4846.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Case A, Deaton A. Deaths of Despair and the Future of Capitalism. Princeton: Princeton University Press; 2021.
2. Case A, Deaton A. The great divide: education, despair, and death. Ann Rev Econom. 2022;14:1-21. doi: 10.1146/annurev-economics-051520-015607
3. Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1-49.
doi: 10.15585/mmwr.rr6501e1
4. Nadeau SE, Wu JK, Lawhern RA. Opioids and chronic pain: an analytic review of the clinical evidence. Frontiers in Pain Research. 2021;2(721357). doi:10.3389/fpain.2021.721357
5. Oliva EM, Bowe T, Tavakoli S, et al. Development and applications of the Veterans Health Administration’s stratification tool for opioid risk mitigation (STORM) to improve opioid safety and prevent overdose and suicide. Psychol Serv. 2017;14(1):34-49. doi: 10.1037/ser0000099
6. Courtwright DT. The History of Opiate Addiction in America. Cambridge: Harvard University Press; 2001.
7. Centers for Disease Control and Prevention. Overdose Death Rates Involving Opioids, by Type, United States, 1999-2020. In. Washington, DC. 2021. https://www.cdc.gov/drugoverdose/data/od-death-data.html
8. Nadeau SE, Lawhern RA. Management of chronic non-cancer pain: a framework. Pain Manag. 2022;ePub(6):751-777. doi:10.2217/pmt-2022-0017
9. Minhee C, Calandrillo S. The cure for America’s opioid crisis? End the war on drugs. Harvard J Law Public Policy. 2019;42:547-623.
10. Dayer LE, Painter JT, McCain K, King J, Cullen J, Foster HR. A recent history of opioid use in the US: Three decades of change. Subst Use Misuse. 2019;54(2):331-339. doi: 10.1080/10826084.2018.1517175
11. Brose WG, Datta D, Kromelow J. Clinical use of opioids for chronic pain. In: Noe CE, ed. Pain Management for clinicians. Switzerland: Springer Nature Switzerland AG; 2020:655-677.
12. Higham S, Horwitz S. American Cartel. Inside the Battle to Bring Down the Opioid Industry. New York, Boston: Twelve; 2022.
13. London C. DOJ overreach: the criminalization of physicians. J Legal Med. 2021;41(3-4):191-203. doi: 10.1080/01947648.2022.2147366
14. Lampe JR. The controlled substances act (CSA): a legal overview for the 117th Congress. 2021. crsreports.congress.gov/product/pdf/download/R/R45948/R45948.pdf/.
15. Drug Enforcement Administration. Diversion Control Division. Automation of Reports and Consolidate Orders System (ARCOS). 2019. https://www.deadiversion.usdoj.gov/arcos/index.html
16. Energy and Commerce Committee. Red flags and warning wigns ignored: opioid distribution and enforcement concerns in West Virginia. In: Representatives USHo, ed2018. 2018. psych-history.weill.cornell.edu/pdf/E_C_Report_West_VA.pdf
17. Randazzo S. States announce $26 billion settlement to resolve opioid lawsuits. Wall Street Journal. 2021. https://www.wsj.com/articles/states-announce-26-billion-settlement-to-resolve-opioid-lawsuits-11626890613
18. James LE. Attorney General James secures $3.1 billion from Walmart for communities nationwide to combat the opioid crisis. 2022. https://ag.ny.gov/press-release/2022/attorney-general-james-secures-31-billion-walmart-communities-nationwide-combat.
19. Distributor Settlement Agreement. https://nj.gov/oag/newsreleases21/Distributors_Settlement.pdf. 2021. Accessed April 18, 2023.
20. Rutkow L, Vernick JS, Alexander GC. More states should regulate pain management clinics to promote public health. Am J Pub Health. 2017;107(2):240-243. doi: 10.2105/AJPH.2016.303568
21. The Heller School for Social Policy and Management. Brandeis University. History of prescription drug monitoring programs. 2018. http://www.pdmpassist.org/
22. Abbasi AB, Salisbury-Afshar E, Berberet CW, Layden JE, Pho MT. Opioid prescribing patterns before fatal opioid overdose. Am J Prev Med. 2020;58:250-253. doi: 10.1016/j.amepre.2019.09.022
23. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Pub Health. 2018;108:182-186. doi: 10.2105/AJPH.2017.304187
24. Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558. doi: 10.1001/jamanetworkopen.2018.0558
25. Hari J. Chasing the Scream. The First and Last Days of the War on Drugs. New York: Bloomsbury Publishing; 2015.
26. Introcaso D. Deaths of despair: the unrecognized tragedy of working clsss immiseration. STAT. 2021. https://www.statnews.com/2021/12/29/deaths-of-despair-unrecognized-tragedy-working-class-immiseration/
27. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Randomized controlled trial. B J Psychiatry. 2007;191:55-62. doi: 10.1192/bjp.bp.106.026112
28. Khoury L, Tang YL, Bradley B, Cubells JF, Ressler KJ. Substance use, childhood traumatic experience, and posttraumatic stress disorder in an urban civilian population. Depress Anxiety. 2010;27:1077-1086. doi: 10.1002/da.20751
29. Friedman SR, Krawczyk N, Perlman DC, et al. The opioid/overdose crisis as a dialectics of pain, despair, and one-sided struggle. Front Pub Health. 2020;8:540423. doi: 10.3389/fpubh.2020.540423
30. Heyman GM, McVicar N, Brownell H. Evidence that social-economic factors play an important role in drug overdose deaths. Int J Drug Policy. 2019;74:274-284. Doi: 10.1016/j.drugpo.2019.07.026
31. Platt L, Minozzi S, Vickerman P, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database for Syst Rev. 2017(9):Art. No.: CD012021. doi:10.1002/14651858.CD012021.pub2(9)
32. Koob GF, Powell P, White A. Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19. Am J Psychiatry. 2020;177(11):1031-1037. doi: 10.1176/appi.ajp.2020. 20091375
33. Robins LN. Vietnam veterans’ rapid recovery from heroin addiction: a fluke or a normal expectation? Addiction. 1993;88:1041-1054.
34. Robins LN, Helzer JE, Hesselbrock M. Vietnam veterans three years after Vietnam: how our study changed our view of heroin. Am J Addictions. 2010;19:203-211. doi: 10.1111/j.1521-0391.2010.00046.x
35. Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. doi: 10.1038/ s41572-019-0137-5
36. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361:eaau1184. doi: 10.1126/science.aau1184
37. Buckley C, Ye Y, Kerr WC, et al. Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment, and race and ethnicity for the United States 2000-2019. BMC Med. 2022;20:405. doi: 10.1186/s12916-022-02590-z
38. Holt-Lunstad J, Perissinotto C. Social isolation and loneliness as medical issues. N Engl J Med. 2023;388(3). doi: 10.1056/NEJMp2208029
39. Lawhern RA. One opioid crisis or many? American Council on Science and Public Health. https://www.acsh.org/news/2018/05/14/one-opioid-crisis-or-many-12956. Accessed May 6, 2023.
40. Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018;193:142-147. doi: 10.1016/j.drugalcdep.2018.10.002
41. Yeh H-H, Peltz-Rauchman C, Johnson CC, et al. Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us research program. PLoS ONE. 2023;18(8):e02904116. doi: 10.1371/journal. pone.0290416
42. Stopka TJ, Larochelle MR, Li X, et al. Opioid-related mortality: Dynamic temporal and spatial trends by drug type and demographic subpopulations, Massachusetts, 2005–2021. Drug Alcohol Depend. 2023;246:109836. doi: 10.1016/j.drugalcdep.2023.109836
43. Banks DE, Scroggins S, Paschke ME, et al. Examining Increasing Racial Inequities in Opioid Overdose Deaths: a Spatiotemporal Analysis of Black and White Decedents in St. Louis, Missouri, 2011–2021. J Urban Health. 2023;100:436-446. doi: 10.1007/s11524-023-00736-9
44. Jones AA, Shearer RD, Segel JE, et al. Opioid and stimulant attributed treatment admissions and fatal overdoses: Using national surveillance data to examine the intersection of race, sex, and polysubstance use, 1992–2020. Drug Alcohol Depend. 2023;249:109946. doi: 10.1016/j.drugalcdep.2023.109946
45. Gibbons JB, Harris SJ, Solomon KT, Sugarman O, Handy C, Saloner B. Increasing overdose deaths among Black Americans: a review of the literature. Lancet Psychiatry. 2023;10:719-726. doi: 10.1016/ S2215-0366(23)00119-0
46. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79-94. doi: 10.1111/papr.12050
47. Rikard SM, Strahan AE, Schmit KM, Guy GP. Chronic pain among adults — United States, 2019-2021. MMWR Morb Mortal Wkly Report. 2023;72(15):379-385. doi: 10.15585/mmwr.mm7215a1.
48. Fudin J. Dancing to the pharmacy crawl for opioids. In. Opioids & Politics, PROMPT (Professionals for Rational Opioid Monitoring & PharmacoTherapy), Substance Abuse & Diversion,. 2012. https://paindr.com/dancing-to-the-pharmacy-crawl-for-opioids/
49. Aubry L, Carr BT. Overdose, opiate treatment admissions and prescription opioid pain reliever relationships: United States 2010-2019. Front Pain Res. 2022;3:884674. doi: 10.3389/fpain.2022.884674
50. Sandbrink F, Murphy JL, Johansson M, et al. The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2023;176:388-397. doi: 10.7326/M22-2917
51. Dawkins R. The Selfish Gene. Oxford: Oxford University Press; 1976.
52. Gleick J. The Information. New York: Random House; 2011.
53. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018;360:j5790. doi: 10.1136/bmj.j5790
54. Gisev N, Buizen L, Hopkins RE, et al. Five-year trajectories of prescription opioid use. JAMA Netw Open. 2023;6(8):e2328159. doi: 10.1001/jamanetworkopen.2023.28159
55. Nadeau SE, DelRocco NJ, Wu SS. Opioid trials: Time for a new approach. Enriched enrollment randomized gradual withdrawal designs. Pain Manag. 2022;12(3):243-247. doi: 10.2217/pmt-2021-0112
56. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321. doi: 10.1001/jama.2011.370
57. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011;5:13-22.
58. Centers for Disease Control and Prevention. CDC Wonder. https://wonder.cdc.gov/ucd-icd10.html. 2019. Accessed 2019.
59. Hart CL. Drug Use for Grown-Ups. New York: Penguin Press; 2021.
60. Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110:244-250. doi: 10.2105/ AJPH.2019.305412
61. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisi KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17:85-98. doi: 10.1111/pme.12907
62. Massachusetts Department of Public Health. An Assessment of Opioid-Related Deaths in Massachusetts (2013-2014). 2016. https://www.mass.gov/doc/legislative-report-chapter-55-opioid-overdose-study-september-2016/download#:~:test=14%20in%202013%2D014%2C%2076,woman%20of%20the%20the%20same%20age
63. Centers for Disease Control and Prevention. SUDORS Dashboard: fatal overdose data. In. Atlanta, GA: Centers for Diease Control and Prevention; 2022. https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html?ACSTrackingID=USCDC_1026-DM85167&ACSTrackingLabel=June%202022%3A%20SUDORS%20Data%20Dashboard%20%2B%20Data%20Brief&deliveryName=USCDC_1026-DM85167
64. Bohnert ASB, Logan JE, Ganoczy D, Dowell D. A detailed exploration into the association of prescribed opioid dosage and overdose deathes among patients with chronic pain. Med Care. 2016;54:435-441. doi: 10.1097/MLR.0000000000000505
65. Hser Y-I, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76-89. doi: 10.1097/HRP.0000000000000052
66. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders — Opioid Use Disorder Diagnostic Criteria. 2013. https://www.google.com/search?q=dsm+v+opioid+use+disorder&ie=utf-8&oe=utf-8&client=firefox-b-1.
67. Nadeau SE. Neural mechanisms of emotions, alexithymia, and depression. Handb Clin Neurol. 2021;183:299-314. doi: 10.1016/B978-0-12-822290-4.00014-1
68. Alexander BK, Beyerstein BL, Hadaway PF, Coambs RB. Effects of early and later colony housing on oral ingestion of morphine in rate. Pharmacol Biochem Behav. 1981;15(4):571-576.
69. Raz S, Berger BD. Social isolation increases morphine intake: behavioral and psychopharmacological aspects. Behav Pharmacol. 2010;21:39-46. doi: 10.1097/FBP.0b013e32833470bd
70. Mosher CJ, Akins S. Drugs and Drug Policy: the Control of Consciousness Alteration. Thousand Oaks, California: Sage Publications; 2007.
71. Gray JP. Why Our Drug Laws Have Failed: A Judicial Indictment of War on Drugs. Philadelphia: Temple University Press; 2001.
72. Thornton M. The Economics of Prohibition. Salt Lake City, UT: University of Utah Press; 1991.
73. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622
74. Zhu H, Wu L-T. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Pub Health. 2018;18:1073. doi: 10.1186/s12889-018-5982-8
75. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev Art. No. CD003410). 2011 doi:10.1002/146518582011.
76. Klimas J, Hamilton M-A, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10:216. doi: 10.1186/s13643-021-01764-9
77. Lim J, Farhat I, Douros A, Panagiotoglou D. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(3):e0266142. doi: 10.1371/journal.pone.0266142
78. Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9:e025799. doi: 10.1136/ bmjopen-2018-025799
79. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550
80. Ma J, Bao Y-P, Wang R-J, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molec Psychiatry. 2019;24:1868-1883. doi: 10.1038/s41380-018-0094-5
81. Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence. A systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976
82. Magwood O, Salvalaggio G, Beder M, et al. The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder. PLoS ONE. 2020;15(1):e0227298. doi: 10.1371/journal.pone.0227298
83. Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188-1209. doi: 10.1111/add.14180
84. Lynn RR, Gatinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63-88. doi: 10.1177/2042098617744161
85. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi: 10.1136/bmj.e5945
86. Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2:1-11.
87. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:235-248. doi: 10.1093/ije/dyt243
88. Krawczyk N, Feder KA, Fingerhhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug Alcohol Depend. 2017;178:512-518. doi: 10.1016/j.drugalcdep.2017.06.009
89. Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57-68. doi: 10.1016/j.jsat.2018.06.001
90. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115:1683-1694. doi: 10.1111/add.14991
91. Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;176:139-147. doi: 10.1016/j.drugalcdep.2017.03.013
92. Dennis ML, Scott CK, Funk R, Foss MA. The duration and correlates of addiction and treatment careers. J Subst Abuse Treat. 2005;28:S51-S62. doi: 10.1016/j.jsat.2004.10.013
93. Hser Y-I, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers. A conceptual framework and existing research findings. J Subst Abuse Treat. 1997;14:543-558. doi: 10.1016/S0740-5472(97)00016-0
94. van Draanen J, Tsang C, Mitra S, et al. Mental disorder and opioid overdose: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2022;57:647-671. doi: 10.1007/s00127-021-02199-2
95. Litz M, Leslie D. The impact of mental health comorbidities on adherence to buprenorphine: a claims based analysis. Am J Addict. 2017;26:859-863. doi: 10.1111/ajad.12644
96. Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50:221-226. doi: 10.1016/s0376-8716(98)00032-5
97. Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord. 2002;72:85-90. doi: 10.1016/s0165-0327(01)00419-0
98. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74:123-134. doi: 10.1016/j.drugalcdep.2003.11.015
99. Poling J, Pruzinski R, Kosten TR, et al. Clinical efficacy of citalopram alone or augmented with bupopion in methadone-stabilized patients. Am J Addict. 2007;16:187-194. doi: 10.1080/10550490701375640
100. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (Review). Cochrane Database Syst Rev. 2011. Pub4(9), Art. No. CD005031doi:10.1002/14651858.CD005031
101. Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174:738-747. doi: 10.1176/appi.ajp.2016.16070792
102. Kumar N, Oles W, Howell BA, et al. The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. J Subst Abuse Treat. 2021;127:108367. doi: 10.1016/j.jsat.2021.108367
103. Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders. A systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e208279. doi: 10.1001/jamanetworkopen.2020.8279
104. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. https://apps.who.int/iris/bitstream/handle/10665/43948/9789241547543_eng.pdf;jsessionid=BD0EE4F2E5BF50DBC1D2BDE6E8518226?sequence=1.
105. Humphreys K, Moos RH. Encouraging posttreatment self-help group involvement to reduce demand for continuing care services: two-year clinical and utilization outcomes. Alcohol Clin Exp Res. 2007;31(1):64-68. doi: 10.1111/j.1530-0277.2006.00273.x
106. Weiss RD, Griffin ML, Marcovitz DE, et al. Correlates of opioid abstinence in a 42-month posttreatment naturalistic follow-up study of prescription opioid dependence. J Clin Psychiatry. 2019;80(2):18m12292. doi: 10.4088/JCP.18m12292
107. Mericle AA, Grella CE. Integrating housing and recovery support services: introduction to the special section. J Dual Diagn. 2016;12(2):150-152. doi: 10.1080/15504263.2016.1176408
108. Laudet AB, Humphreys K. Promoting recovery in an evolving policy context: What do we know and what do we need to know about recovery support services? J Subst Abuse Treat. 2013;45:126-133. doi: 10.1016/j.jsat.2013.01.009
109. Laudet AB, Stanick V, Sands B. What could the program have done differently? A qualitative examination of reasons for leaving outpatient treatment. J Subst Abuse Treat. 2009;37:182-190. doi: 10.1016/j.jsat.2009.01.001
110. Best DDW, Ghufran S, Ray R, Loaring J. Breaking the habit: a retrospective analysis of desistance factors among formerly problematic heroin users Drug Alcohol Rev. 2008;27(6):619-624. doi: 10.1080/09595230802392808
111. Gruber K, Chutuape MA, Stitzer ML. Reinforcement-based intensive outpatient treatment for inner city opiate abusers: a short-term evaluation. Drug Alcohol Depend. 2000;57:211-223. doi: 10.1016/s0376-8716(99)00054-x
112. Jones HE, Wong CJ, Tuten M, Stitzer ML. Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers. Drug Alcohol Depend. 2005;79:119-128. doi: 10.1016/j.drugalcdep.2005.01.006
113. Tuten M, DeFulio A, Jones HE, Stitzer M. Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction. 2011;107:973-982. doi: 10.1111/j.1360-0443.2011.03750.x
114. Brigham GS, Slesnick N, Winhusen W, Lewis DF, Guo X, Somoza E. A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug Alcohol Depend. 2014;138:240-243. doi: 10.1016/j.drugalcdep.2014.02.013
115. Chutuape MA, Katz EC, Stitzer ML. Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend. 2001;61:137-143. doi: 10.1016/s0376-8716(00)00133-2
116. Zaller ND, Thurmond P, Brett J, Carleton JC, Rich JD. Linkage to methadone treatment from acute opiate detoxification treatment. J Opioid Manag. 2006;2(6):341-346. doi: 10.5055/jom.2006.0050
117. Kennedy MC, Karamouzian M, Kerr T. Public healthand public order outcomes associated with supervised drug consumption facilities: a systematic review. Current HIV/AIDS Reports. 2017;14:161-183. doi: 10.1007/s11904-017-0363-y
118. Potier C, Laprévote V, Dubois-Arber F, Cottensin O, Rolland B. Supervised injection services: What has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48-68. doi: 10.1016/j.drugalcdep.2014.10.012
119. Kennedy MC, Karamouzian M, Marshall BDL. The North American opioid crisis: how effective are supervised consumption sites? Lancet. 2022;400:1403-1404. doi: 10.1016/S0140-6736(22)01593-8
120. McNeil R, Small W. ‘Safer environment interventions’: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151-158.doi: 10.1016/j.socscimed.2014.01.051
121. European Monitoring Centre for Drugs and Drug Addiction. Drug consumption rooms: an overview of provisionand evidence. 2018, https://www.emcdda.europa.eu/topics/drug-consumption-facilities_en. Accessed October 31, 2022.
122. Tran V, Reid SE, Roxburgh A, Day CA. Assessing drug consumption rooms and longer term (5 year) impacts on community and clients. Risk Manag Health Policy. 2021;14(14):4639-4647. doi: 10.2147/RMHP.S244720. eCollection 2021
123. Yoon GH, Levengood TW, Davoust MJ, et al. Implementation and sustainability of safe consumption sites: a qualitative systematic review and thematic synthesis. Harm Reduct J. 2022;19:73.doi: 10.1186/s12954-022-00655-z
124. Levengood TW, Yoon GH, Davoust MJ, et al. Supervised injection facilities as harm reduction: A systematic review. Am J Prevent Med. 2021(5):738-749. doi: 10.1016/j.amepre.2021.04.017
125. Palis H, Harrison S, Macdonald S, Marsh DC, Schechter MT, Oviedo-Joekes E. Self-managing illicit stimulant use: A qualitative study with patients receiving injectable opioid agonist treatment. Drug Alcohol Rev. 2020;39:914-923. doi: 10.1111/dar.13117
126. Feldman AE, Manna V. New York City allows opening of safe illegal drug use sites, first in the nation. Spectrum News NY1. 2021. ). https://www.ny1.com/nyc/all-boroughs/news/2021/11/30/new-york-city-allows-opening-of-safe-illegal-drug-use-sites--first-in-the-nation
127. Hayle S. A tale of two Canadian cities: Comparing supervised consumption site (SCS) policy making in Toronto and Vancouver. Drugs Educat Prevent Policy. 2018;25(5):397-407. doi: 10.1080/09687637.2017.1292215
128. Small D, Palepu A, Tyndall MW. The establishment of North America’s first state sanctioned supervised injection facility: A case study in culture change. Int J Drug Policy. 2006;17:73-82. doi:10.1016/j.drugpo.2005.08.004
129. Centers for Disease Control and Prevention. Fentanyl test strips: a harm reduction strategy. 2023. ). https://www.cdc.gov/stopoverdose/fentanyl/fentanyl-test-strips.html#print
130. Caulkins JP, Pardo B, Kilmer B. Supervised consumptions sites: a nuanced assessment of the causal evidence. Addiction. 2019;114:2109-2115. doi: 10.1111/add.14747
131. Earp BD, Lewis J, Hart CL, Bioethicists and Allied Professionals for Drug Policy Reform. Racial justice requires ending the war on drug. Am J Bioeth. 2021;21(4):4-19. doi: 10.1080/15265161.2020.1861364
132. 29 countries. 49 models of drug decriminalisation. One handy web-tool. 2020. https://www.talkingdrugs.org/decriminalisation. Accessed November 14, 2022.
133. van het Loo M, van Beusekom I, Kahan JP. Decriminalization of drug use in Portugal: the development of a policy. Ann AAPSS. 2002;582:49-63. doi: 10.1177/000271620258200104
134. Greenwald G. Drug decriminalization in Portugal. Lessons for creating fair and successful drug policies. 2009. https://www.cato.org/white-paper/drug-decriminalization-portugal-lessons-creating-fair-successful-drug-policies#. Accessed November 14, 2022.
135. European Monitoring Centre for Drugs and Drug Addiction. Portugal Country Drug Report 2019;1-31. 1-31 https://www.emcdda.europa.eu/publications/country-drug-reports/2019/portugal_en
136. Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Br J Criminol. 2010;50:999-1022. doi: 10.1093/bjc/azq038
137. Hughes CE, Stevens A. A resounding success or a disastrous failure: Re-examining the interpretation of evidence on the Portuguese decriminalisation of illicit drugs. Drug Alcohol Rev. 2012;31:101-113. doi: 10.1111/j.1465-3362.2011.00383.x
138. Humphreys K, Shover CM, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission. Lancet. 2022:1-48. doi: 10.1016/ S0140-6736(21)02252-2
139. Office of Management and Budget. Budget of the U.S. Government. In. Wasington, D.C. 2022. https://www.whitehouse.gov/wp-content/uploads/2021/05/budget_fy22.pdf
140. Conçalves R, Lourenço A, Nogueira da Silva S. A social cost perspective in the wake of the Portuguese strategy for the fight against drugs. Int J Drug Policy. 2015;26:199-209.doi: 10.1016/j.drugpo.2014.08.017
141. Csete J. What the world can learn from drug policty change in Switzerland. 2013. https://www.opensocietyfoundations.org/publications/mountaintops#:~:text=From%20the%20Mountaintops%3A%20What%20the%20World%20Can%20Learn,rates%2C%20improve%20health%20outcomes%2C%20and%20lower%20crime%20rates. Accessed November 21, 2022.
142. Jauffret-Roustide M, Houborg E, Southwell M, et al. Different Paths and Potentials to Harm Reduction in Different Welfare States: Drug Consumption Rooms in the United Kingdom, Denmark, and France Am J Public Health. 2022;112(52):S99-S103. doi: 10.2105/AJPH.2022.306790
143. Faiola A, Fernandez Martins C. Once hailed for decriminalizing drugs, Portugal is now having doubts. The Washington Post. July 7, 2023. https://www.washingtonpost.com/world/2023/07/07/portugal-drugs-decriminalization-heroin-crack/
144. Hinch J. What happened when Oregon decriminalized hard drugs. The Atlantic 2023. https://www.theatlantic.com/politics/archive/2023/07/oregon-drug-decriminalization-results-overdoses/674733/
145. Miron J, Partin E. Ending the war on drugs is an essential step toward racial justice. Am J Bioeth. 2021;21(4):1-3. doi: 10.1080/15265161.2021.1895590
146. Strombotne KL, Legler A, Minegishi T, et al. Effect of a predictive analytics-targeted program in patients on opioids: a stepped-wedge cluster randomized controlled trial. J Gen Intern Med. 2022;38(2):375-381. doi: 10.1007/s11606-022-07617-y
147. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice gudeline for prescribing opioids for pain — Unitest States, 2022. MMWR Morb Mort Wkly Report. 2022;71(3):1-95.doi: 10.15585/mmwr.rr7103a1
148. Sagan C. The Demon-Haunted World. Science as a Candle in the Dark. New York: Ballantine Books; 1996.
149. Lewis M. The Premonition. New York: W.W. Norton; 2021.
150. Kollas C. PROP’s disproportionate influence on U.S. opioid policy: the harms of intended consequences. Pallimed. A Hospice & Palliative Medicine Blog. 2021. https://www.pallimed.org/2021/05/props-disproportionate-influence-on-us.html#disqus_thread. Published 2021. Accessed May 6, 2023.
151. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose. Ann Int Med. 2010;152:85-92. doi: 10.7326/0003-4819-152-2-201001190-00006
152. Coppola V. A plague of politics. In. Atlanta Magazine. Atlanta, GA. 1994. https://www.atlantamagazine.com/great-reads/a-plague-of-politics/
153. Califano moves to remove doctor who guided swine flu program. New York Times. February 8, 1977. https://www.nytimes.com/1977/02/08/archives/califano-moves-to-remove-doctor-who-guided-swine-flu-program-flu.html
154. Centers for Disease Control and Prevention. Provisional drug overdose death counts. 2023. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
155. World Health Organization. WHO Model list of essential medicines. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/ essential-medicines-lists. Published 2020. Accessed December 2. 2022.
156. Gupta R, Levine RL, Cepeda JA, Holtgrave DR. Transforming management of opioid use disorder with universal treatment. N Engl J Med. 2022;387:1341-1344. doi: 10.1056/NEJMp2210121
157. United States Congress. H.R.2617 — Consolidated Appropriations Act, 2023. 2022. https://www.congress.gov/bill/117th-congress/house-bill/2617/text
158. Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. In: Health and Human Services. 2023. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement
159. Poorman E. The number needed to prescribe — what would it take to expand access to buprenorphine. N Engl J Med. 2021;384:383-384. doi: 10.1056/NEJMp2101298
160. Wakeman SE, Beletsky L. Beyond the X — next steps in policy reforms to address the opioid crisis. N Engl J Med. 2023;388(18):1639-1641.doi: 10.1056/NEJMp2301479
161. Substance Abuse and Mental Health Services Administration. Federal laws related to SAMSA. SUPPORT Act. 2022. ). https://www.samhsa.gov/about-us/who-we-are/laws-regulations
162. 115 United States Congress. Public Law 115-271. Substance use-disorder prevention that promotes opioid recovery and treatment for patients and communities Act. 2018. https://uscode.house.gov/statutes/pl/115/271.pdf
163. Substance Abuse and Mental Health Services Administration. SAMHSA Interim Strategic Plan. 2023. https://www.samhsa.gov/about-us/interim-strategic-plan
164. Chandler RK, Villani J, Clark T, McCrance EF, Volkow ND. Addressing opioid overdose deaths: The vision for the HEALing communities study. Drug Alcohol Depend. 2020;271:108239. doi: 10.1016/j.drugalcdep.2020.108329
165. Winhusen T, Walley A, Fanucchi LC, et al. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing communities study. Drug Alcohol Depend. 2020;271:108325. doi: 10.1016/j.drugalcdep.2020.108325
2. Case A, Deaton A. The great divide: education, despair, and death. Ann Rev Econom. 2022;14:1-21. doi: 10.1146/annurev-economics-051520-015607
3. Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1-49.
doi: 10.15585/mmwr.rr6501e1
4. Nadeau SE, Wu JK, Lawhern RA. Opioids and chronic pain: an analytic review of the clinical evidence. Frontiers in Pain Research. 2021;2(721357). doi:10.3389/fpain.2021.721357
5. Oliva EM, Bowe T, Tavakoli S, et al. Development and applications of the Veterans Health Administration’s stratification tool for opioid risk mitigation (STORM) to improve opioid safety and prevent overdose and suicide. Psychol Serv. 2017;14(1):34-49. doi: 10.1037/ser0000099
6. Courtwright DT. The History of Opiate Addiction in America. Cambridge: Harvard University Press; 2001.
7. Centers for Disease Control and Prevention. Overdose Death Rates Involving Opioids, by Type, United States, 1999-2020. In. Washington, DC. 2021. https://www.cdc.gov/drugoverdose/data/od-death-data.html
8. Nadeau SE, Lawhern RA. Management of chronic non-cancer pain: a framework. Pain Manag. 2022;ePub(6):751-777. doi:10.2217/pmt-2022-0017
9. Minhee C, Calandrillo S. The cure for America’s opioid crisis? End the war on drugs. Harvard J Law Public Policy. 2019;42:547-623.
10. Dayer LE, Painter JT, McCain K, King J, Cullen J, Foster HR. A recent history of opioid use in the US: Three decades of change. Subst Use Misuse. 2019;54(2):331-339. doi: 10.1080/10826084.2018.1517175
11. Brose WG, Datta D, Kromelow J. Clinical use of opioids for chronic pain. In: Noe CE, ed. Pain Management for clinicians. Switzerland: Springer Nature Switzerland AG; 2020:655-677.
12. Higham S, Horwitz S. American Cartel. Inside the Battle to Bring Down the Opioid Industry. New York, Boston: Twelve; 2022.
13. London C. DOJ overreach: the criminalization of physicians. J Legal Med. 2021;41(3-4):191-203. doi: 10.1080/01947648.2022.2147366
14. Lampe JR. The controlled substances act (CSA): a legal overview for the 117th Congress. 2021. crsreports.congress.gov/product/pdf/download/R/R45948/R45948.pdf/.
15. Drug Enforcement Administration. Diversion Control Division. Automation of Reports and Consolidate Orders System (ARCOS). 2019. https://www.deadiversion.usdoj.gov/arcos/index.html
16. Energy and Commerce Committee. Red flags and warning wigns ignored: opioid distribution and enforcement concerns in West Virginia. In: Representatives USHo, ed2018. 2018. psych-history.weill.cornell.edu/pdf/E_C_Report_West_VA.pdf
17. Randazzo S. States announce $26 billion settlement to resolve opioid lawsuits. Wall Street Journal. 2021. https://www.wsj.com/articles/states-announce-26-billion-settlement-to-resolve-opioid-lawsuits-11626890613
18. James LE. Attorney General James secures $3.1 billion from Walmart for communities nationwide to combat the opioid crisis. 2022. https://ag.ny.gov/press-release/2022/attorney-general-james-secures-31-billion-walmart-communities-nationwide-combat.
19. Distributor Settlement Agreement. https://nj.gov/oag/newsreleases21/Distributors_Settlement.pdf. 2021. Accessed April 18, 2023.
20. Rutkow L, Vernick JS, Alexander GC. More states should regulate pain management clinics to promote public health. Am J Pub Health. 2017;107(2):240-243. doi: 10.2105/AJPH.2016.303568
21. The Heller School for Social Policy and Management. Brandeis University. History of prescription drug monitoring programs. 2018. http://www.pdmpassist.org/
22. Abbasi AB, Salisbury-Afshar E, Berberet CW, Layden JE, Pho MT. Opioid prescribing patterns before fatal opioid overdose. Am J Prev Med. 2020;58:250-253. doi: 10.1016/j.amepre.2019.09.022
23. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Pub Health. 2018;108:182-186. doi: 10.2105/AJPH.2017.304187
24. Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558. doi: 10.1001/jamanetworkopen.2018.0558
25. Hari J. Chasing the Scream. The First and Last Days of the War on Drugs. New York: Bloomsbury Publishing; 2015.
26. Introcaso D. Deaths of despair: the unrecognized tragedy of working clsss immiseration. STAT. 2021. https://www.statnews.com/2021/12/29/deaths-of-despair-unrecognized-tragedy-working-class-immiseration/
27. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence. Randomized controlled trial. B J Psychiatry. 2007;191:55-62. doi: 10.1192/bjp.bp.106.026112
28. Khoury L, Tang YL, Bradley B, Cubells JF, Ressler KJ. Substance use, childhood traumatic experience, and posttraumatic stress disorder in an urban civilian population. Depress Anxiety. 2010;27:1077-1086. doi: 10.1002/da.20751
29. Friedman SR, Krawczyk N, Perlman DC, et al. The opioid/overdose crisis as a dialectics of pain, despair, and one-sided struggle. Front Pub Health. 2020;8:540423. doi: 10.3389/fpubh.2020.540423
30. Heyman GM, McVicar N, Brownell H. Evidence that social-economic factors play an important role in drug overdose deaths. Int J Drug Policy. 2019;74:274-284. Doi: 10.1016/j.drugpo.2019.07.026
31. Platt L, Minozzi S, Vickerman P, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database for Syst Rev. 2017(9):Art. No.: CD012021. doi:10.1002/14651858.CD012021.pub2(9)
32. Koob GF, Powell P, White A. Addiction as a coping response: hyperkatifeia, deaths of despair, and COVID-19. Am J Psychiatry. 2020;177(11):1031-1037. doi: 10.1176/appi.ajp.2020. 20091375
33. Robins LN. Vietnam veterans’ rapid recovery from heroin addiction: a fluke or a normal expectation? Addiction. 1993;88:1041-1054.
34. Robins LN, Helzer JE, Hesselbrock M. Vietnam veterans three years after Vietnam: how our study changed our view of heroin. Am J Addictions. 2010;19:203-211. doi: 10.1111/j.1521-0391.2010.00046.x
35. Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. doi: 10.1038/ s41572-019-0137-5
36. Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science. 2018;361:eaau1184. doi: 10.1126/science.aau1184
37. Buckley C, Ye Y, Kerr WC, et al. Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment, and race and ethnicity for the United States 2000-2019. BMC Med. 2022;20:405. doi: 10.1186/s12916-022-02590-z
38. Holt-Lunstad J, Perissinotto C. Social isolation and loneliness as medical issues. N Engl J Med. 2023;388(3). doi: 10.1056/NEJMp2208029
39. Lawhern RA. One opioid crisis or many? American Council on Science and Public Health. https://www.acsh.org/news/2018/05/14/one-opioid-crisis-or-many-12956. Accessed May 6, 2023.
40. Huhn AS, Strain EC, Tompkins DA, Dunn KE. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend. 2018;193:142-147. doi: 10.1016/j.drugalcdep.2018.10.002
41. Yeh H-H, Peltz-Rauchman C, Johnson CC, et al. Examining sociodemographic correlates of opioid use, misuse, and use disorders in the All of Us research program. PLoS ONE. 2023;18(8):e02904116. doi: 10.1371/journal. pone.0290416
42. Stopka TJ, Larochelle MR, Li X, et al. Opioid-related mortality: Dynamic temporal and spatial trends by drug type and demographic subpopulations, Massachusetts, 2005–2021. Drug Alcohol Depend. 2023;246:109836. doi: 10.1016/j.drugalcdep.2023.109836
43. Banks DE, Scroggins S, Paschke ME, et al. Examining Increasing Racial Inequities in Opioid Overdose Deaths: a Spatiotemporal Analysis of Black and White Decedents in St. Louis, Missouri, 2011–2021. J Urban Health. 2023;100:436-446. doi: 10.1007/s11524-023-00736-9
44. Jones AA, Shearer RD, Segel JE, et al. Opioid and stimulant attributed treatment admissions and fatal overdoses: Using national surveillance data to examine the intersection of race, sex, and polysubstance use, 1992–2020. Drug Alcohol Depend. 2023;249:109946. doi: 10.1016/j.drugalcdep.2023.109946
45. Gibbons JB, Harris SJ, Solomon KT, Sugarman O, Handy C, Saloner B. Increasing overdose deaths among Black Americans: a review of the literature. Lancet Psychiatry. 2023;10:719-726. doi: 10.1016/ S2215-0366(23)00119-0
46. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79-94. doi: 10.1111/papr.12050
47. Rikard SM, Strahan AE, Schmit KM, Guy GP. Chronic pain among adults — United States, 2019-2021. MMWR Morb Mortal Wkly Report. 2023;72(15):379-385. doi: 10.15585/mmwr.mm7215a1.
48. Fudin J. Dancing to the pharmacy crawl for opioids. In. Opioids & Politics, PROMPT (Professionals for Rational Opioid Monitoring & PharmacoTherapy), Substance Abuse & Diversion,. 2012. https://paindr.com/dancing-to-the-pharmacy-crawl-for-opioids/
49. Aubry L, Carr BT. Overdose, opiate treatment admissions and prescription opioid pain reliever relationships: United States 2010-2019. Front Pain Res. 2022;3:884674. doi: 10.3389/fpain.2022.884674
50. Sandbrink F, Murphy JL, Johansson M, et al. The use of opioids in the management of chronic pain: synopsis of the 2022 updated U.S. department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2023;176:388-397. doi: 10.7326/M22-2917
51. Dawkins R. The Selfish Gene. Oxford: Oxford University Press; 1976.
52. Gleick J. The Information. New York: Random House; 2011.
53. Brat GA, Agniel D, Beam A, et al. Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study. BMJ. 2018;360:j5790. doi: 10.1136/bmj.j5790
54. Gisev N, Buizen L, Hopkins RE, et al. Five-year trajectories of prescription opioid use. JAMA Netw Open. 2023;6(8):e2328159. doi: 10.1001/jamanetworkopen.2023.28159
55. Nadeau SE, DelRocco NJ, Wu SS. Opioid trials: Time for a new approach. Enriched enrollment randomized gradual withdrawal designs. Pain Manag. 2022;12(3):243-247. doi: 10.2217/pmt-2021-0112
56. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315-1321. doi: 10.1001/jama.2011.370
57. Gomes T, Juurlink DN, Dhalla IA, Mailis-Gagnon A, Paterson JM, Mamdani MM. Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Med. 2011;5:13-22.
58. Centers for Disease Control and Prevention. CDC Wonder. https://wonder.cdc.gov/ucd-icd10.html. 2019. Accessed 2019.
59. Hart CL. Drug Use for Grown-Ups. New York: Penguin Press; 2021.
60. Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110:244-250. doi: 10.2105/ AJPH.2019.305412
61. Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisi KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. 2016;17:85-98. doi: 10.1111/pme.12907
62. Massachusetts Department of Public Health. An Assessment of Opioid-Related Deaths in Massachusetts (2013-2014). 2016. https://www.mass.gov/doc/legislative-report-chapter-55-opioid-overdose-study-september-2016/download#:~:test=14%20in%202013%2D014%2C%2076,woman%20of%20the%20the%20same%20age
63. Centers for Disease Control and Prevention. SUDORS Dashboard: fatal overdose data. In. Atlanta, GA: Centers for Diease Control and Prevention; 2022. https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html?ACSTrackingID=USCDC_1026-DM85167&ACSTrackingLabel=June%202022%3A%20SUDORS%20Data%20Dashboard%20%2B%20Data%20Brief&deliveryName=USCDC_1026-DM85167
64. Bohnert ASB, Logan JE, Ganoczy D, Dowell D. A detailed exploration into the association of prescribed opioid dosage and overdose deathes among patients with chronic pain. Med Care. 2016;54:435-441. doi: 10.1097/MLR.0000000000000505
65. Hser Y-I, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015;23(2):76-89. doi: 10.1097/HRP.0000000000000052
66. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders — Opioid Use Disorder Diagnostic Criteria. 2013. https://www.google.com/search?q=dsm+v+opioid+use+disorder&ie=utf-8&oe=utf-8&client=firefox-b-1.
67. Nadeau SE. Neural mechanisms of emotions, alexithymia, and depression. Handb Clin Neurol. 2021;183:299-314. doi: 10.1016/B978-0-12-822290-4.00014-1
68. Alexander BK, Beyerstein BL, Hadaway PF, Coambs RB. Effects of early and later colony housing on oral ingestion of morphine in rate. Pharmacol Biochem Behav. 1981;15(4):571-576.
69. Raz S, Berger BD. Social isolation increases morphine intake: behavioral and psychopharmacological aspects. Behav Pharmacol. 2010;21:39-46. doi: 10.1097/FBP.0b013e32833470bd
70. Mosher CJ, Akins S. Drugs and Drug Policy: the Control of Consciousness Alteration. Thousand Oaks, California: Sage Publications; 2007.
71. Gray JP. Why Our Drug Laws Have Failed: A Judicial Indictment of War on Drugs. Philadelphia: Temple University Press; 2001.
72. Thornton M. The Economics of Prohibition. Salt Lake City, UT: University of Utah Press; 1991.
73. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622
74. Zhu H, Wu L-T. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Pub Health. 2018;18:1073. doi: 10.1186/s12889-018-5982-8
75. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev Art. No. CD003410). 2011 doi:10.1002/146518582011.
76. Klimas J, Hamilton M-A, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10:216. doi: 10.1186/s13643-021-01764-9
77. Lim J, Farhat I, Douros A, Panagiotoglou D. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. PLoS ONE. 2022;17(3):e0266142. doi: 10.1371/journal.pone.0266142
78. Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9:e025799. doi: 10.1136/ bmjopen-2018-025799
79. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi: 10.1136/bmj.j1550
80. Ma J, Bao Y-P, Wang R-J, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Molec Psychiatry. 2019;24:1868-1883. doi: 10.1038/s41380-018-0094-5
81. Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence. A systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976
82. Magwood O, Salvalaggio G, Beder M, et al. The effectiveness of substance use interventions for homeless and vulnerably housed persons: A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder. PLoS ONE. 2020;15(1):e0227298. doi: 10.1371/journal.pone.0227298
83. Jarvis BP, Holtyn AF, Subramaniam S, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188-1209. doi: 10.1111/add.14180
84. Lynn RR, Gatinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018;9(1):63-88. doi: 10.1177/2042098617744161
85. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi: 10.1136/bmj.e5945
86. Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2:1-11.
87. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:235-248. doi: 10.1093/ije/dyt243
88. Krawczyk N, Feder KA, Fingerhhood MI, Saloner B. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. Drug Alcohol Depend. 2017;178:512-518. doi: 10.1016/j.drugalcdep.2017.06.009
89. Williams AR, Nunes EV, Bisaga A, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57-68. doi: 10.1016/j.jsat.2018.06.001
90. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115:1683-1694. doi: 10.1111/add.14991
91. Eastwood B, Strang J, Marsden J. Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England. Drug Alcohol Depend. 2017;176:139-147. doi: 10.1016/j.drugalcdep.2017.03.013
92. Dennis ML, Scott CK, Funk R, Foss MA. The duration and correlates of addiction and treatment careers. J Subst Abuse Treat. 2005;28:S51-S62. doi: 10.1016/j.jsat.2004.10.013
93. Hser Y-I, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers. A conceptual framework and existing research findings. J Subst Abuse Treat. 1997;14:543-558. doi: 10.1016/S0740-5472(97)00016-0
94. van Draanen J, Tsang C, Mitra S, et al. Mental disorder and opioid overdose: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2022;57:647-671. doi: 10.1007/s00127-021-02199-2
95. Litz M, Leslie D. The impact of mental health comorbidities on adherence to buprenorphine: a claims based analysis. Am J Addict. 2017;26:859-863. doi: 10.1111/ajad.12644
96. Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend. 1998;50:221-226. doi: 10.1016/s0376-8716(98)00032-5
97. Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord. 2002;72:85-90. doi: 10.1016/s0165-0327(01)00419-0
98. Carpenter KM, Brooks AC, Vosburg SK, Nunes EV. The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend. 2004;74:123-134. doi: 10.1016/j.drugalcdep.2003.11.015
99. Poling J, Pruzinski R, Kosten TR, et al. Clinical efficacy of citalopram alone or augmented with bupopion in methadone-stabilized patients. Am J Addict. 2007;16:187-194. doi: 10.1080/10550490701375640
100. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification (Review). Cochrane Database Syst Rev. 2011. Pub4(9), Art. No. CD005031doi:10.1002/14651858.CD005031
101. Carroll KM, Weiss RD. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174:738-747. doi: 10.1176/appi.ajp.2016.16070792
102. Kumar N, Oles W, Howell BA, et al. The role of social network support in treatment outcomes for medication for opioid use disorder: A systematic review. J Subst Abuse Treat. 2021;127:108367. doi: 10.1016/j.jsat.2021.108367
103. Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders. A systematic review and meta-analysis. JAMA Netw Open. 2020;3(6):e208279. doi: 10.1001/jamanetworkopen.2020.8279
104. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. https://apps.who.int/iris/bitstream/handle/10665/43948/9789241547543_eng.pdf;jsessionid=BD0EE4F2E5BF50DBC1D2BDE6E8518226?sequence=1.
105. Humphreys K, Moos RH. Encouraging posttreatment self-help group involvement to reduce demand for continuing care services: two-year clinical and utilization outcomes. Alcohol Clin Exp Res. 2007;31(1):64-68. doi: 10.1111/j.1530-0277.2006.00273.x
106. Weiss RD, Griffin ML, Marcovitz DE, et al. Correlates of opioid abstinence in a 42-month posttreatment naturalistic follow-up study of prescription opioid dependence. J Clin Psychiatry. 2019;80(2):18m12292. doi: 10.4088/JCP.18m12292
107. Mericle AA, Grella CE. Integrating housing and recovery support services: introduction to the special section. J Dual Diagn. 2016;12(2):150-152. doi: 10.1080/15504263.2016.1176408
108. Laudet AB, Humphreys K. Promoting recovery in an evolving policy context: What do we know and what do we need to know about recovery support services? J Subst Abuse Treat. 2013;45:126-133. doi: 10.1016/j.jsat.2013.01.009
109. Laudet AB, Stanick V, Sands B. What could the program have done differently? A qualitative examination of reasons for leaving outpatient treatment. J Subst Abuse Treat. 2009;37:182-190. doi: 10.1016/j.jsat.2009.01.001
110. Best DDW, Ghufran S, Ray R, Loaring J. Breaking the habit: a retrospective analysis of desistance factors among formerly problematic heroin users Drug Alcohol Rev. 2008;27(6):619-624. doi: 10.1080/09595230802392808
111. Gruber K, Chutuape MA, Stitzer ML. Reinforcement-based intensive outpatient treatment for inner city opiate abusers: a short-term evaluation. Drug Alcohol Depend. 2000;57:211-223. doi: 10.1016/s0376-8716(99)00054-x
112. Jones HE, Wong CJ, Tuten M, Stitzer ML. Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers. Drug Alcohol Depend. 2005;79:119-128. doi: 10.1016/j.drugalcdep.2005.01.006
113. Tuten M, DeFulio A, Jones HE, Stitzer M. Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction. 2011;107:973-982. doi: 10.1111/j.1360-0443.2011.03750.x
114. Brigham GS, Slesnick N, Winhusen W, Lewis DF, Guo X, Somoza E. A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug Alcohol Depend. 2014;138:240-243. doi: 10.1016/j.drugalcdep.2014.02.013
115. Chutuape MA, Katz EC, Stitzer ML. Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend. 2001;61:137-143. doi: 10.1016/s0376-8716(00)00133-2
116. Zaller ND, Thurmond P, Brett J, Carleton JC, Rich JD. Linkage to methadone treatment from acute opiate detoxification treatment. J Opioid Manag. 2006;2(6):341-346. doi: 10.5055/jom.2006.0050
117. Kennedy MC, Karamouzian M, Kerr T. Public healthand public order outcomes associated with supervised drug consumption facilities: a systematic review. Current HIV/AIDS Reports. 2017;14:161-183. doi: 10.1007/s11904-017-0363-y
118. Potier C, Laprévote V, Dubois-Arber F, Cottensin O, Rolland B. Supervised injection services: What has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014;145:48-68. doi: 10.1016/j.drugalcdep.2014.10.012
119. Kennedy MC, Karamouzian M, Marshall BDL. The North American opioid crisis: how effective are supervised consumption sites? Lancet. 2022;400:1403-1404. doi: 10.1016/S0140-6736(22)01593-8
120. McNeil R, Small W. ‘Safer environment interventions’: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151-158.doi: 10.1016/j.socscimed.2014.01.051
121. European Monitoring Centre for Drugs and Drug Addiction. Drug consumption rooms: an overview of provisionand evidence. 2018, https://www.emcdda.europa.eu/topics/drug-consumption-facilities_en. Accessed October 31, 2022.
122. Tran V, Reid SE, Roxburgh A, Day CA. Assessing drug consumption rooms and longer term (5 year) impacts on community and clients. Risk Manag Health Policy. 2021;14(14):4639-4647. doi: 10.2147/RMHP.S244720. eCollection 2021
123. Yoon GH, Levengood TW, Davoust MJ, et al. Implementation and sustainability of safe consumption sites: a qualitative systematic review and thematic synthesis. Harm Reduct J. 2022;19:73.doi: 10.1186/s12954-022-00655-z
124. Levengood TW, Yoon GH, Davoust MJ, et al. Supervised injection facilities as harm reduction: A systematic review. Am J Prevent Med. 2021(5):738-749. doi: 10.1016/j.amepre.2021.04.017
125. Palis H, Harrison S, Macdonald S, Marsh DC, Schechter MT, Oviedo-Joekes E. Self-managing illicit stimulant use: A qualitative study with patients receiving injectable opioid agonist treatment. Drug Alcohol Rev. 2020;39:914-923. doi: 10.1111/dar.13117
126. Feldman AE, Manna V. New York City allows opening of safe illegal drug use sites, first in the nation. Spectrum News NY1. 2021. ). https://www.ny1.com/nyc/all-boroughs/news/2021/11/30/new-york-city-allows-opening-of-safe-illegal-drug-use-sites--first-in-the-nation
127. Hayle S. A tale of two Canadian cities: Comparing supervised consumption site (SCS) policy making in Toronto and Vancouver. Drugs Educat Prevent Policy. 2018;25(5):397-407. doi: 10.1080/09687637.2017.1292215
128. Small D, Palepu A, Tyndall MW. The establishment of North America’s first state sanctioned supervised injection facility: A case study in culture change. Int J Drug Policy. 2006;17:73-82. doi:10.1016/j.drugpo.2005.08.004
129. Centers for Disease Control and Prevention. Fentanyl test strips: a harm reduction strategy. 2023. ). https://www.cdc.gov/stopoverdose/fentanyl/fentanyl-test-strips.html#print
130. Caulkins JP, Pardo B, Kilmer B. Supervised consumptions sites: a nuanced assessment of the causal evidence. Addiction. 2019;114:2109-2115. doi: 10.1111/add.14747
131. Earp BD, Lewis J, Hart CL, Bioethicists and Allied Professionals for Drug Policy Reform. Racial justice requires ending the war on drug. Am J Bioeth. 2021;21(4):4-19. doi: 10.1080/15265161.2020.1861364
132. 29 countries. 49 models of drug decriminalisation. One handy web-tool. 2020. https://www.talkingdrugs.org/decriminalisation. Accessed November 14, 2022.
133. van het Loo M, van Beusekom I, Kahan JP. Decriminalization of drug use in Portugal: the development of a policy. Ann AAPSS. 2002;582:49-63. doi: 10.1177/000271620258200104
134. Greenwald G. Drug decriminalization in Portugal. Lessons for creating fair and successful drug policies. 2009. https://www.cato.org/white-paper/drug-decriminalization-portugal-lessons-creating-fair-successful-drug-policies#. Accessed November 14, 2022.
135. European Monitoring Centre for Drugs and Drug Addiction. Portugal Country Drug Report 2019;1-31. 1-31 https://www.emcdda.europa.eu/publications/country-drug-reports/2019/portugal_en
136. Hughes CE, Stevens A. What can we learn from the Portuguese decriminalization of illicit drugs? Br J Criminol. 2010;50:999-1022. doi: 10.1093/bjc/azq038
137. Hughes CE, Stevens A. A resounding success or a disastrous failure: Re-examining the interpretation of evidence on the Portuguese decriminalisation of illicit drugs. Drug Alcohol Rev. 2012;31:101-113. doi: 10.1111/j.1465-3362.2011.00383.x
138. Humphreys K, Shover CM, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission. Lancet. 2022:1-48. doi: 10.1016/ S0140-6736(21)02252-2
139. Office of Management and Budget. Budget of the U.S. Government. In. Wasington, D.C. 2022. https://www.whitehouse.gov/wp-content/uploads/2021/05/budget_fy22.pdf
140. Conçalves R, Lourenço A, Nogueira da Silva S. A social cost perspective in the wake of the Portuguese strategy for the fight against drugs. Int J Drug Policy. 2015;26:199-209.doi: 10.1016/j.drugpo.2014.08.017
141. Csete J. What the world can learn from drug policty change in Switzerland. 2013. https://www.opensocietyfoundations.org/publications/mountaintops#:~:text=From%20the%20Mountaintops%3A%20What%20the%20World%20Can%20Learn,rates%2C%20improve%20health%20outcomes%2C%20and%20lower%20crime%20rates. Accessed November 21, 2022.
142. Jauffret-Roustide M, Houborg E, Southwell M, et al. Different Paths and Potentials to Harm Reduction in Different Welfare States: Drug Consumption Rooms in the United Kingdom, Denmark, and France Am J Public Health. 2022;112(52):S99-S103. doi: 10.2105/AJPH.2022.306790
143. Faiola A, Fernandez Martins C. Once hailed for decriminalizing drugs, Portugal is now having doubts. The Washington Post. July 7, 2023. https://www.washingtonpost.com/world/2023/07/07/portugal-drugs-decriminalization-heroin-crack/
144. Hinch J. What happened when Oregon decriminalized hard drugs. The Atlantic 2023. https://www.theatlantic.com/politics/archive/2023/07/oregon-drug-decriminalization-results-overdoses/674733/
145. Miron J, Partin E. Ending the war on drugs is an essential step toward racial justice. Am J Bioeth. 2021;21(4):1-3. doi: 10.1080/15265161.2021.1895590
146. Strombotne KL, Legler A, Minegishi T, et al. Effect of a predictive analytics-targeted program in patients on opioids: a stepped-wedge cluster randomized controlled trial. J Gen Intern Med. 2022;38(2):375-381. doi: 10.1007/s11606-022-07617-y
147. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice gudeline for prescribing opioids for pain — Unitest States, 2022. MMWR Morb Mort Wkly Report. 2022;71(3):1-95.doi: 10.15585/mmwr.rr7103a1
148. Sagan C. The Demon-Haunted World. Science as a Candle in the Dark. New York: Ballantine Books; 1996.
149. Lewis M. The Premonition. New York: W.W. Norton; 2021.
150. Kollas C. PROP’s disproportionate influence on U.S. opioid policy: the harms of intended consequences. Pallimed. A Hospice & Palliative Medicine Blog. 2021. https://www.pallimed.org/2021/05/props-disproportionate-influence-on-us.html#disqus_thread. Published 2021. Accessed May 6, 2023.
151. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose. Ann Int Med. 2010;152:85-92. doi: 10.7326/0003-4819-152-2-201001190-00006
152. Coppola V. A plague of politics. In. Atlanta Magazine. Atlanta, GA. 1994. https://www.atlantamagazine.com/great-reads/a-plague-of-politics/
153. Califano moves to remove doctor who guided swine flu program. New York Times. February 8, 1977. https://www.nytimes.com/1977/02/08/archives/califano-moves-to-remove-doctor-who-guided-swine-flu-program-flu.html
154. Centers for Disease Control and Prevention. Provisional drug overdose death counts. 2023. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
155. World Health Organization. WHO Model list of essential medicines. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/ essential-medicines-lists. Published 2020. Accessed December 2. 2022.
156. Gupta R, Levine RL, Cepeda JA, Holtgrave DR. Transforming management of opioid use disorder with universal treatment. N Engl J Med. 2022;387:1341-1344. doi: 10.1056/NEJMp2210121
157. United States Congress. H.R.2617 — Consolidated Appropriations Act, 2023. 2022. https://www.congress.gov/bill/117th-congress/house-bill/2617/text
158. Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. In: Health and Human Services. 2023. https://www.samhsa.gov/medications-substance-use-disorders/removal-data-waiver-requirement
159. Poorman E. The number needed to prescribe — what would it take to expand access to buprenorphine. N Engl J Med. 2021;384:383-384. doi: 10.1056/NEJMp2101298
160. Wakeman SE, Beletsky L. Beyond the X — next steps in policy reforms to address the opioid crisis. N Engl J Med. 2023;388(18):1639-1641.doi: 10.1056/NEJMp2301479
161. Substance Abuse and Mental Health Services Administration. Federal laws related to SAMSA. SUPPORT Act. 2022. ). https://www.samhsa.gov/about-us/who-we-are/laws-regulations
162. 115 United States Congress. Public Law 115-271. Substance use-disorder prevention that promotes opioid recovery and treatment for patients and communities Act. 2018. https://uscode.house.gov/statutes/pl/115/271.pdf
163. Substance Abuse and Mental Health Services Administration. SAMHSA Interim Strategic Plan. 2023. https://www.samhsa.gov/about-us/interim-strategic-plan
164. Chandler RK, Villani J, Clark T, McCrance EF, Volkow ND. Addressing opioid overdose deaths: The vision for the HEALing communities study. Drug Alcohol Depend. 2020;271:108239. doi: 10.1016/j.drugalcdep.2020.108329
165. Winhusen T, Walley A, Fanucchi LC, et al. The opioid-overdose reduction continuum of care approach (ORCCA): evidence-based practices in the HEALing communities study. Drug Alcohol Depend. 2020;271:108325. doi: 10.1016/j.drugalcdep.2020.108325